Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ID: NCT07007312
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".
Read Full Scientific Objectives & Methods
This protocol encompasses two phase 3, randomized, double-blind, placebo-controlled clinical studies to assess the efficacy, safety, and tolerability of ziftomenib in combination with: (a) the standard of care (SOC) nonintensive regimen (venetoclax \[ven\]+azacitidine \[aza\]) in untreated adults with nucleophosmin 1 mutated (NPM1-m) acute myeloid leukemia (AML); or (b) the SOC intensive regimen (cytarabine+daunorubicin induction, referred to here as 7+3, and cytarabine consolidation) in untreated adults with NPM1-m or lysine\[K\]-specific methyltransferase 2A rearranged (KMT2A-r) AML, as well as a maintenance phase. Nonintensive Therapy Study (Ven+Aza) Eligible NPM1-m patients will be enrolled and randomized to receive: * Arm A: Ziftomenib in combination with ven+aza or * Arm B: Placebo in combination with ven+aza. Patients will be randomized to treatment arms in a double-blind manner. Intensive Therapy Study (Cytarabine+Daunorubicin) Eligible NPM1-m or KMT2A-r patients will be enrolled and randomized to 1 of the following treatment arms: * Arm A: Ziftomenib+7+3 (induction), ziftomenib+cytarabine (consolidation), ziftomenib (maintenance) or * Arm B: Ziftomenib+7+3 (induction), ziftomenib+cytarabine (consolidation), placebo (maintenance) or * Arm C: Placebo+7+3 (induction), placebo+cytarabine (consolidation), placebo (maintenance). Patients will be randomized to treatment arms in a double-blind manner.
Oral administration
Oral administration
Oral administration
Intravenous or subcutaneous administration
Intravenous administration
Intravenous administration
Treatment Arms Description
Ziftomenib in combination with venetoclax+azacitidine
Placebo in combination with venetoclax+azacitidine
Ziftomenib+cytarabine+daunorubicin (induction), ziftomenib+cytarabine (consolidation), ziftomenib (maintenance)
Ziftomenib+cytarabine+daunorubicin (induction), ziftomenib+cytarabine (consolidation), placebo (maintenance)
Placebo+cytarabine+daunorubicin (induction), placebo+cytarabine (consolidation), placebo (maintenance)
- The following criteria apply to both the Nonintensive Therapy Study and the Intensive Therapy Study unless otherwise noted:
- Age ≥18 years at time of signing the informed consent form.
- Diagnosis of AML per the 2022 WHO Classification of Hematolymphoid Tumors (5th Edition).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Adequate liver and kidney function according to protocol requirements.
- A female of childbearing potential must agree to use adequate contraception from the time of screening through 180 days following the last dose of study intervention. A male with a female partner of childbearing potential must agree to use abstinence or adequate contraception from the time of screening through 90 days following the last dose of study intervention.
- NONINTENSIVE THERAPY STUDY ONLY (VEN+AZA):
- Documented NPM1-m.
- Patients considered ineligible for Intensive Therapy defined by the following:
- i. Age ≥75, OR
- ii. Age \<75 with an ECOG performance status of 2 or cardiac, renal, or hepatic impairment per protocol criteria.
- INTENSIVE THERAPY STUDY ONLY (7+3):
- Documented NPM1-m or KMT2A-r (KMT2A-r patients with a partial tandem duplication are not eligible).
- Documented FLT3 wild-type or ITD ratio \<0.05 OR ineligible to receive FLT3-targeted therapy (medically ineligible or mutation in which FLT3 inhibition is not SOC). Lack of access to an FLT3 inhibitor is not considered "ineligible" for FLT3-targeted therapy.
- Ejection fraction of ≥50%.
- Fit for Intensive Therapy per Investigator opinion.
- Prior therapy for AML (except hydroxyurea or leukapheresis for WBC control).
- Diagnosis of acute promyelocytic leukemia (APL), blast phase chronic myeloid leukemia, or isolated myeloid sarcoma.
- Known history of BCR-ABL mutation.
- History of other active concurrent malignancies prior to study entry except:
- Basal cell skin cancer or localized squamous cell cancer of the skin
- Previous malignancy confined and locally resected (or treated with other modalities) with curative intent
- Prostate or breast cancer receiving adjuvant hormonal therapy.
- Active central nervous system (CNS) involvement by AML.
- Clinical signs/symptoms of leukostasis or white blood cells (WBC) \>25×10\^9/L prior to start of ziftomenib/placebo. Note: Hydroxyurea and/or leukapheresis are permitted to meet this criterion.
- Known uncontrolled HIV infection or known active hepatitis B virus, hepatitis C virus infection, or other uncontrolled infection.
- Uncontrolled intercurrent illness including but not limited to, cardiac illness as defined in the protocol.
- Women who are pregnant or lactating.
Primary Outcome Measures
- Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) — Time Frame: Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion
OS
- Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) — Time Frame: Assessed up to 36 months after last patient inclusion
CR rate per European Leukemia Network (ELN) 2022 criteria per Investigator assessment
- Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS) — Time Frame: Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion
EFS
- Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients — Time Frame: Assessed up to 36 months after last patient inclusion
CR rate per ELN 2022 criteria per Investigator assessment with central BM MRD negativity
View Secondary Outcome Measures (13)
- Nonintensive Therapy Study: (EU & EU reference countries only): Complete remission (CR) — Time Frame: Up to 36 months after last patient inclusion
CR rate per ELN 2022 criteria per Investigator assessment
- Nonintensive Therapy Study: Bone marrow (BM) measurable residual disease (MRD) negativity — Time Frame: Up to 36 months after last patient inclusion
Central BM MRD negativity rate
- Nonintensive Therapy Study: Complete remission (CR) + complete remission with partial hematologic recovery (CRh) — Time Frame: Up to 36 months after last patient inclusion
CR + CRh rate per ELN 2022 criteria per Investigator assessment
- Nonintensive Therapy Study: Descriptive statistics of Adverse Events (AEs) — Time Frame: From start of treatment to 28 days from last dose of ziftomenib or placebo
Assessed by NCI-CTCAE v5.0
- Nonintensive Therapy Study: Area under the concentration-time curve (AUC) of ziftomenib and venetoclax — Time Frame: During treatment for up to 36 months after last patient inclusion
To characterize the AUC of ziftomenib and venetoclax
- Nonintensive Therapy Study: Trough concentration (Ctrough) of ziftomenib and venetoclax — Time Frame: During treatment for up to 36 months after last patient inclusion
To characterize the Ctrough of ziftomenib and venetoclax
- Nonintensive Therapy Study: Health-related patient-reported outcomes (PRO) assessments — Time Frame: Up to 36 months after last patient inclusion
Health-related quality of life (HRQoL) was evaluated by EORTC QLQ-C30 global health status/quality of life composite scale in all randomized participants. The QLQ-C30 is a cancer-specific, self-administered questionnaire that contains 30 questions, covering global, functional, and symptom scales. Scores range from 0 to 100. Higher scores on global and functional scales indicated better quality of life (QoL), while higher scores on the symptom scales indicated declining QoL.
- Intensive Therapy Study: (EU & EU reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients — Time Frame: Up to 36 months after last patient inclusion
CR rate per ELN 2022 criteria per Investigator assessment with central BM MRD negativity
- Intensive Therapy Study: Overall survival (OS) — Time Frame: Defined as the time from randomization to date of death from any cause, up to 36 months after last patient inclusion
OS
- Intensive Therapy Study: Descriptive statistics of Adverse Events (AEs) — Time Frame: From start of treatment to 28 days from last dose of ziftomenib or placebo
Assessed by NCI-CTCAE v5.0
This trial is recruiting at 136 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 136 Facilities & Contact Sites
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
View Official Medical/Scientific Title
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia